Key result
Treating primary aldosteronism links to a ~15 mL/min eGFR decline, predicted by pretreatment aldosterone excess.
Why the study?
Longstanding primary aldosteronism has deleterious effects on renal function that are often masked until treatment is initiated, and the mechanisms of eGFR decline after treatment are not fully understood.
Does treatment for primary aldosteronism (adrenalectomy or spironolactone) reduce eGFR in patients with primary aldosteronism?
Cohort (n=134)
Does treatment for primary aldosteronism (adrenalectomy or spironolactone) reduce eGFR in patients with primary aldosteronism?
Treatment of primary aldosteronism unmasks underlying renal dysfunction, leading to a significant decline in eGFR that is primarily driven by the severity of pretreatment aldosterone excess.
Longstanding primary aldosteronism (PA) has deleterious effects on renal function, often masked until treatment (adrenalectomy or spironolactone) is initiated. It has been suggested that PA causes relative glomerular hyperfiltration, explaining the decline in estimated glomerular filtration rate (eGFR) after treatment. In this retrospective study, the authors retrieved the clinical characteristics and eGFR of 134 PA patients before and 6 months after treatment. Using multiple regression analysis, the predictors for eGFR decline and the predictors of ultimately attained renal function in 113 patients was assessed. eGFR declined by 15.3±14.2 (range 19-63) mL/min, independent predictors were pretreatment plasma aldosterone, eGFR, plasma renin, and plasma potassium. Independent predictors of ultimately attained eGFR after treatment were pretreatment plasma aldosterone, age, eGFR, and plasma potassium. Our findings lend support to the hypothesis that higher aldosterone levels cause relative glomerular hyperfiltration. The severity of pretreatment aldosterone excess is the most important risk factor for renal function decline.
No takes yet. Share an insight, caveat, or question.
Kramers et al. (2016) conducted a cohort in Primary aldosteronism (n=134). Treatment (adrenalectomy or spironolactone) vs. Pretreatment baseline was evaluated on Decline in estimated glomerular filtration rate (eGFR). Treatment of primary aldosteronism led to an eGFR decline of 15.3±14.2 mL/min at 6 months, with the severity of pretreatment aldosterone excess being the most important risk factor for decline.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: